Dolby Laboratories (DLB) Stock Forecast, Price Target & Predictions
DLB Stock Forecast
Dolby Laboratories stock forecast is as follows: an average price target of $90.00 (represents a 22.20% upside from DLB’s last price of $73.65) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
DLB Price Target
The average price target for Dolby Laboratories (DLB) is $90.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $90.00. This represents a potential 22.20% upside from DLB's last price of $73.65.
DLB Analyst Ratings
According to 2 Wall Street analysts, Dolby Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for DLB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dolby Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 03, 2023 | - | Rosenblatt Securities | $90.00 | $82.67 | 8.87% | 22.20% |
The latest Dolby Laboratories stock forecast, released on Feb 03, 2023 by Rosenblatt Securities company, set a price target of $90.00, which represents a 8.87% increase from the stock price at the time of the forecast ($82.67), and a 22.20% increase from DLB last price ($73.65).
Dolby Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $73.65 | $73.65 | $73.65 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Dolby Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dolby Laboratories's last price of $73.65. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 07, 2024 | Rosenblatt Securities | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Dolby Laboratories's last stock rating was published by Rosenblatt Securities on Jun 07, 2024. The company gave DLB a "Buy" rating, the same as its previous rate.
Dolby Laboratories Financial Forecast
Dolby Laboratories Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $290.56M | $298.37M | $375.89M | $334.92M | $278.20M | $289.58M | $334.37M | $351.63M | $285.02M | $286.80M | $319.56M | $389.87M | $271.19M | $246.91M | $351.81M | $291.88M | $298.83M | $302.16M | $338.26M | $301.36M | $267.47M | $233.00M |
| Avg Forecast | $322.34M | $302.77M | $371.34M | $337.94M | $307.94M | $292.85M | $359.43M | $312.16M | $290.20M | $301.66M | $349.85M | $306.56M | $305.23M | $293.92M | $332.51M | $359.38M | $299.95M | $278.79M | $294.29M | $345.33M | $244.43M | $232.61M | $361.35M | $285.81M | $297.55M | $305.29M | $337.45M | $290.62M | $256.58M | $202.61M |
| High Forecast | $322.34M | $302.77M | $371.34M | $337.94M | $313.00M | $293.20M | $359.43M | $321.41M | $295.30M | $301.66M | $349.85M | $306.56M | $305.23M | $293.92M | $332.51M | $359.38M | $299.95M | $278.79M | $294.29M | $345.33M | $244.43M | $232.61M | $361.35M | $285.81M | $297.55M | $305.29M | $337.45M | $348.74M | $307.90M | $243.13M |
| Low Forecast | $322.34M | $302.77M | $371.34M | $337.94M | $303.28M | $292.49M | $359.43M | $303.12M | $280.15M | $301.66M | $349.85M | $306.56M | $305.23M | $293.92M | $332.51M | $359.38M | $299.95M | $278.79M | $294.29M | $345.33M | $244.43M | $232.61M | $361.35M | $285.81M | $297.55M | $305.29M | $337.45M | $232.49M | $205.27M | $162.09M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 8 | 5 | 4 | 9 | 6 | 4 | 11 | 15 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 0.99% | 1.07% | 1.09% | 0.91% | 0.99% | 1.01% | 0.98% | 0.95% | 1.03% | 1.09% | 1.13% | 1.11% | 1.06% | 0.97% | 1.02% | 1.00% | 0.99% | 1.00% | 1.04% | 1.04% | 1.15% |
Dolby Laboratories's average Quarter revenue forecast for Dec 23 based on 3 analysts is $312.16M, with a low forecast of $303.12M, and a high forecast of $321.41M. DLB's average Quarter revenue forecast represents a 7.43% increase compared to the company's last Quarter revenue of $290.56M (Sep 23).
Dolby Laboratories EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 8 | 5 | 4 | 9 | 6 | 4 | 11 | 15 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $81.95M | $15.94M | $109.29M | $122.18M | $35.69M | $77.73M | $75.06M | $118.85M | $42.51M | $82.67M | $111.51M | $185.37M | $34.50M | $65.23M | $130.45M | $75.44M | $84.92M | $94.08M | $130.82M | $110.15M | $88.48M | $52.16M |
| Avg Forecast | $93.76M | $88.07M | $108.02M | $98.30M | $89.57M | $85.18M | $74.48M | $90.80M | $84.41M | $87.75M | $67.71M | $137.02M | $88.78M | $85.50M | $61.55M | $104.54M | $87.25M | $81.09M | $71.01M | $100.45M | $71.10M | $67.66M | $136.59M | $83.14M | $86.55M | $88.80M | $85.44M | $105.04M | $84.59M | $44.22M |
| High Forecast | $93.76M | $88.07M | $108.02M | $98.30M | $91.05M | $85.29M | $89.38M | $93.49M | $85.90M | $87.75M | $81.25M | $164.42M | $88.78M | $85.50M | $73.86M | $104.54M | $87.25M | $81.09M | $85.21M | $100.45M | $71.10M | $67.66M | $163.91M | $83.14M | $86.55M | $88.80M | $102.52M | $126.05M | $101.50M | $53.07M |
| Low Forecast | $93.76M | $88.07M | $108.02M | $98.30M | $88.22M | $85.08M | $59.58M | $88.17M | $81.49M | $87.75M | $54.17M | $109.61M | $88.78M | $85.50M | $49.24M | $104.54M | $87.25M | $81.09M | $56.80M | $100.45M | $71.10M | $67.66M | $109.27M | $83.14M | $86.55M | $88.80M | $68.35M | $84.03M | $67.67M | $35.38M |
| Surprise % | - | - | - | - | - | - | - | - | 0.97% | 0.18% | 1.61% | 0.89% | 0.40% | 0.91% | 1.22% | 1.14% | 0.49% | 1.02% | 1.57% | 1.85% | 0.49% | 0.96% | 0.96% | 0.91% | 0.98% | 1.06% | 1.53% | 1.05% | 1.05% | 1.18% |
3 analysts predict DLB's average Quarter EBITDA for Dec 23 to be $90.80M, with a high of $93.49M and a low of $88.17M. This is 10.79% upper than Dolby Laboratories's previous annual EBITDA (Sep 23) of $81.95M.
Dolby Laboratories Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 8 | 5 | 4 | 9 | 6 | 4 | 11 | 15 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $9.19M | $31.11M | $95.70M | $79.38M | $27.76M | $39.60M | $36.72M | $80.01M | $44.19M | $54.62M | $76.22M | $135.20M | $26.83M | $67.28M | $88.50M | $48.75M | $43.92M | $39.57M | $73.44M | $70.63M | $50.59M | $23.93M |
| Avg Forecast | $55.19M | $49.82M | $84.00M | $82.05M | $43.47M | $29.79M | $39.01M | $51.86M | $21.63M | $27.14M | $35.47M | $92.17M | $39.56M | $34.47M | $32.24M | $77.66M | $34.43M | $26.95M | $48.92M | $77.75M | $14.46M | $8.01M | $92.56M | $29.69M | $47.23M | $47.67M | $48.02M | $63.16M | $48.44M | $20.34M |
| High Forecast | $55.19M | $49.82M | $84.00M | $82.05M | $46.66M | $29.79M | $46.82M | $52.44M | $22.45M | $27.14M | $42.56M | $110.60M | $39.56M | $34.47M | $38.69M | $77.66M | $34.43M | $26.95M | $58.70M | $77.75M | $14.46M | $8.01M | $111.07M | $29.69M | $47.23M | $47.67M | $57.62M | $75.80M | $58.12M | $24.41M |
| Low Forecast | $55.19M | $49.82M | $84.00M | $82.05M | $40.91M | $29.79M | $31.21M | $50.69M | $20.41M | $27.14M | $28.37M | $73.73M | $39.56M | $34.47M | $25.79M | $77.66M | $34.43M | $26.95M | $39.13M | $77.75M | $14.46M | $8.01M | $74.04M | $29.69M | $47.23M | $47.67M | $38.41M | $50.53M | $38.75M | $16.27M |
| Surprise % | - | - | - | - | - | - | - | - | 0.42% | 1.15% | 2.70% | 0.86% | 0.70% | 1.15% | 1.14% | 1.03% | 1.28% | 2.03% | 1.56% | 1.74% | 1.86% | 8.40% | 0.96% | 1.64% | 0.93% | 0.83% | 1.53% | 1.12% | 1.04% | 1.18% |
Dolby Laboratories's average Quarter net income forecast for Dec 23 is $51.86M, with a range of $50.69M to $52.44M. DLB's average Quarter net income forecast represents a 464.50% increase compared to the company's last Quarter net income of $9.19M (Sep 23).
Dolby Laboratories SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 8 | 5 | 4 | 9 | 6 | 4 | 11 | 15 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $157.48M | $155.55M | $157.63M | $142.18M | $147.27M | $144.23M | $182.92M | $159.61M | $152.66M | $136.83M | $137.44M | $129.90M | $136.98M | $121.78M | $149.28M | $147.65M | $135.16M | $137.57M | $140.11M | $124.77M | $118.87M | $114.49M |
| Avg Forecast | $149.06M | $140.01M | $171.72M | $156.28M | $142.40M | $135.42M | $194.34M | $144.35M | $134.20M | $139.50M | $176.68M | $183.86M | $141.15M | $135.92M | $160.62M | $166.19M | $138.71M | $128.92M | $88.21M | $159.69M | $113.03M | $107.57M | $156.13M | $132.17M | $137.60M | $141.18M | $91.61M | $120.90M | $113.81M | $97.31M |
| High Forecast | $149.06M | $140.01M | $171.72M | $156.28M | $144.74M | $135.59M | $233.21M | $148.63M | $136.56M | $139.50M | $212.01M | $220.63M | $141.15M | $135.92M | $192.74M | $166.19M | $138.71M | $128.92M | $105.85M | $159.69M | $113.03M | $107.57M | $187.36M | $132.17M | $137.60M | $141.18M | $109.93M | $145.08M | $136.58M | $116.78M |
| Low Forecast | $149.06M | $140.01M | $171.72M | $156.28M | $140.25M | $135.26M | $155.48M | $140.17M | $129.55M | $139.50M | $141.34M | $147.09M | $141.15M | $135.92M | $128.49M | $166.19M | $138.71M | $128.92M | $70.57M | $159.69M | $113.03M | $107.57M | $124.91M | $132.17M | $137.60M | $141.18M | $73.29M | $96.72M | $91.05M | $77.85M |
| Surprise % | - | - | - | - | - | - | - | - | 1.17% | 1.12% | 0.89% | 0.77% | 1.04% | 1.06% | 1.14% | 0.96% | 1.10% | 1.06% | 1.56% | 0.81% | 1.21% | 1.13% | 0.96% | 1.12% | 0.98% | 0.97% | 1.53% | 1.03% | 1.04% | 1.18% |
Dolby Laboratories's average Quarter SG&A projection for Dec 23 is $144.35M, based on 3 Wall Street analysts, with a range of $140.17M to $148.63M. The forecast indicates a -8.34% fall compared to DLB last annual SG&A of $157.48M (Sep 23).
Dolby Laboratories EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 8 | 5 | 4 | 9 | 6 | 4 | 11 | 15 | 11 |
| EPS | - | - | - | - | - | - | - | - | $0.10 | $0.33 | $1.00 | $0.83 | $0.29 | $0.40 | $0.36 | $0.79 | $0.44 | $0.54 | $0.75 | $1.34 | $0.27 | $0.67 | $0.88 | $0.49 | $0.44 | $0.39 | $0.72 | $0.68 | $0.50 | $0.24 |
| Avg Forecast | $0.56 | $0.51 | $0.86 | $0.84 | $0.45 | $0.30 | $1.01 | $0.53 | $0.22 | $0.28 | $0.68 | $0.48 | $0.41 | $0.35 | $0.52 | $0.80 | $0.35 | $0.28 | $0.46 | $0.80 | $0.15 | $0.08 | $0.90 | $0.30 | $0.48 | $0.49 | $0.52 | $0.62 | $0.45 | $0.17 |
| High Forecast | $0.56 | $0.51 | $0.86 | $0.84 | $0.48 | $0.30 | $1.01 | $0.54 | $0.23 | $0.28 | $0.68 | $0.48 | $0.41 | $0.35 | $0.52 | $0.80 | $0.35 | $0.28 | $0.46 | $0.80 | $0.15 | $0.08 | $0.90 | $0.30 | $0.48 | $0.49 | $0.52 | $0.74 | $0.54 | $0.20 |
| Low Forecast | $0.56 | $0.51 | $0.86 | $0.84 | $0.42 | $0.30 | $1.01 | $0.52 | $0.21 | $0.28 | $0.68 | $0.48 | $0.41 | $0.35 | $0.52 | $0.80 | $0.35 | $0.28 | $0.46 | $0.80 | $0.15 | $0.08 | $0.90 | $0.30 | $0.48 | $0.49 | $0.52 | $0.50 | $0.36 | $0.14 |
| Surprise % | - | - | - | - | - | - | - | - | 0.45% | 1.19% | 1.48% | 1.71% | 0.72% | 1.13% | 0.69% | 0.99% | 1.25% | 1.96% | 1.64% | 1.68% | 1.82% | 8.17% | 0.98% | 1.61% | 0.91% | 0.80% | 1.39% | 1.10% | 1.11% | 1.41% |
According to 3 Wall Street analysts, Dolby Laboratories's projected average Quarter EPS for Dec 23 is $0.53, with a low estimate of $0.52 and a high estimate of $0.54. This represents a 430.88% increase compared to DLB previous annual EPS of $0.10 (Sep 23).
Dolby Laboratories Peer Comparison by Price Target
DLB Forecast FAQ
Is Dolby Laboratories a good buy?
Yes, according to 2 Wall Street analysts, Dolby Laboratories (DLB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of DLB's total ratings.
What is DLB's price target?
Dolby Laboratories (DLB) average price target is $90 with a range of $90 to $90, implying a 22.20% from its last price of $73.65. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Dolby Laboratories stock go up soon?
According to Wall Street analysts' prediction for DLB stock, the company can go up by 22.20% (from the last price of $73.65 to the average price target of $90), up by 22.20% based on the highest stock price target, and up by 22.20% based on the lowest stock price target.
Can Dolby Laboratories stock reach $110?
DLB's average twelve months analyst stock price target of $90 does not support the claim that Dolby Laboratories can reach $110 in the near future.
What are Dolby Laboratories's analysts' financial forecasts?
Dolby Laboratories's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $1.25B (high $1.27B, low $1.24B), average EBITDA is $334.88M (high $354.05M, low $314.33M), average net income is $142.29M (high $151.49M, low $132.1M), average SG&A $608.32M (high $653.99M, low $560.46M), and average EPS is $2.07 (high $2.08, low $2.04). DLB's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $1.32B (high $1.33B, low $1.32B), average EBITDA is $383.96M (high $385.43M, low $382.6M), average net income is $259.34M (high $262.53M, low $256.78M), average SG&A $610.41M (high $612.75M, low $608.25M), and average EPS is $2.65 (high $2.69, low $2.63).
Did the DLB's actual financial results beat the analysts' financial forecasts?
Based on Dolby Laboratories's last annual report (Jun 2023), the company's revenue was $1.01B, which missed the average analysts forecast of $1.26B by -20.12%. Apple's EBITDA was $219.25M, missing the average prediction of $381.26M by -42.49%. The company's net income was $191.47M, missing the average estimation of $194.33M by -1.47%. Apple's SG&A was $455.36M, missing the average forecast of $641.18M by -28.98%. Lastly, the company's EPS was $2, beating the average prediction of $1.85 by 8.36%. In terms of the last quarterly report (Sep 2023), Dolby Laboratories's revenue was $290.56M, beating the average analysts' forecast of $290.2M by 0.13%. The company's EBITDA was $81.96M, missing the average prediction of $84.41M by -2.91%. Dolby Laboratories's net income was $9.19M, missing the average estimation of $21.63M by -57.54%. The company's SG&A was $157.48M, beating the average forecast of $134.2M by 17.35%. Lastly, the company's EPS was $0.1, missing the average prediction of $0.221 by -54.85%